Sponsored

Zelira Therapeutics, Emyria join hands to trial HOPE™ Products for Autism patients

  • November 23, 2020 05:24 PM AEDT
  • Kunal Sawhney
    CEO Kunal Sawhney
    2781 Posts

    Kunal Sawhney is founder & CEO at Kalkine and is a richly experienced and accomplished financial professional with a wealth of knowledge in the Australian Equities Market. Kunal obtained a Master of Business Administration degree from University of T...

Zelira Therapeutics, Emyria join hands to trial HOPE™ Products for Autism patients

Summary

  • Leading biopharmaceutical company Zelira Therapeutics signed an agreement with Emyria Ltd for Autism Observational Trial of HOPE™ products.
  • The Trial will collect efficacy and safety data from patients diagnosed with ASD and have been given one or more HOPE™ products.
  • The agreement will expand the global commercialisation opportunities for Zelira.
  • The Observational Trial data advise the design of possible future clinical trials and will speed up the path to regulatory approval.
Gold MTF non-AMP

ASX-listed leading global therapeutic medical cannabis player Zelira Therapeutics Limited (ASX:ZLD, OTCQB:ZLDAF) owns a rich portfolio of proprietary revenue-generating cannabinoid-based products that have been launched into global markets. The Company is focused on the development of branded cannabis medicines for the treatment of several medical indications.

Zelira Therapeutics has developed the HOPE™ range of products targeting Autism Spectrum Disorder (ASD). HOPE™ products have been launched and are generating revenues in Pennsylvania and Louisiana and Australia. Lately, the Company signed an agreement with Emyria Ltd (ASX:EMD) for Autism Observational Trial of HOPE™ Products.

Zelira’s agreement with Emyria to study HOPE™ Products

On 9 November 2020, Zelira Therapeutics Limited updated the market that the Company had entered into an agreement with Emyria Ltd for an Observational Trial of Zelira’s HOPE™ range of products in ASD patients.

Emyria Ltd is a reputed global leader dealing with the collection and translation of real-world patient data (RWD). It also owns and manages a national network of specialist medical clinics.

As part of the deal, Zelira will receive longitudinal-RWD from Emyria collected from ASD patients who were administered a HOPE™ product. The data would comprise the patient’s efficacy and safety relating to comorbidities, associated medications, information related to dosing and patient responses to HOPE™ treatment (evaluated through standard ASD clinical and behavioural endpoints).

Zelira will pay a fee of A$115,000 to Emyria in two instalments over the first six months, and a subscription fee for each patient enrolled in the Trial, up to a maximum of 150 volunteers. The agreement term is for 12 months with an option to extend the subscription fees on an ongoing basis.

It is noteworthy to mention that this agreement further accelerates global commercialisation opportunities for HOPE™ products.

The partnership with Emyria underpins Zelira’s competitive advantage in developing high-value medicinal cannabinoid products to market, backed by clinical as well as real-world patient data.

Observational Trial of HOPE™ Products

The Observational Trial will collect efficacy and safety data from patients diagnosed with ASD and have been given one or more HOPE™ products.

This Trial will be one of the most extensive medicinal cannabis studies ever conducted for a specific range of products in ASD patients. The study design will increase strategic engagement with major stakeholders in the Autism community and streamline patient access via Emerald Clinics (Emyria’s national network of specialist medical clinics).

Moreover, this focussed method will generate high-quality, real-world patient data (RWD) that will complement Zelira’s existing data-pack for HOPE™ and notify the Company’s global marketing strategy in real-time.

The study data will also aid in the design of possible future clinical trials, lessen the risks and developmental costs, and speed up the path to regulatory approval.

Notably, these efforts will complement and strengthen the latest launch of HOPE™ products across the Australian market.

Zelira’s HOPE™ products for autism

Zelira has two proprietary formulations under the HOPE™ brand - HOPE 1™ and HOPE 2™.  HOPE™ products are part of Zelira’s family of revenue-generating medicinal cannabis products.

The products comprise two pharmaceutical-grade proprietary formulations developed as pharmaceutical-grade products targeting ASD as a disease.

Recently, on 27 October 2020, the Company announced the launch of its HOPE™ products in Australia, marking a significant milestone towards the global commercialisation of HOPE™ products. The Australian launch took place after Therapeutic Goods Administration (TGA) added them to the Special Access Scheme (SAS).

In August 2020, the Company launched HOPE™ products under license in the American state, Louisiana in partnership with Advanced Biomedics LLC.

 

Adding to this, Dr Michael Winlo, Managing Director of Emyria, said-

Bottomline

The agreement with Emyria adds lustre to the launch of HOPE™ in Australia and accelerates global commercialisation opportunities for HOPE™ products. Additionally, the data from the Trial will also expedite the path to patients and accelerate route to regulatory approval.

On 23 November 2020, ZLD shares traded at A$0.077, up by 13.235%.

 

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK